Puma Biotech Surges, Defying Yellen
PUMA BIOTECHNOLOGY, INC.
ST – Puma Biotechnology Partnership - Specialised Therapeutics
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
Puma Biotechnology, Inc. (PBYI) BCG Matrix Analysis
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
pbyi-10k_20171231.htm
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC | Nasdaq
Puma Biotechnology
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated) -November 22, 2023 at 04:30 am EST | MarketScreener
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology, Inc. - SEC Filings - Annual Reports & Proxies
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
Puma Biotechnology
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotech punts near $300 million on Takeda discard
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now | Nasdaq
